// App-Quantinova.ai

11517 : Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).

Researchers

Presenter

  • Steven Attia

Principal Investigators

  • Victor Manuel Villalobos

  • Nadia Hindi

  • Brian Andrew Van Tine

  • Andrew J. Wagner

  • Bartosz Chmielowski

  • Donna Elise Levy

  • Matteo Ceccarelli

  • Robin Lewis Jones

  • Mark Andrew Dickson

Medical Centers

  • Mayo Clinic, Jacksonville, FL

  • University of Colorado Denver School of Medicine, Aurora, CO

  • Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla and Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain

  • Division of Oncology, Washington University in St. Louis, St. Louis, MO

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • UCLA and the Jonsson Comprehensive Cancer Center, Los Angeles, CA

  • Syneos Health, Morrisville, NC

  • Eli Lilly and Company, Indianapolis, IN

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Spain

  • United Kingdom

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Musculoskeletal

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Soft tissue sarcoma

  • Leiomyosarcoma

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Olaratumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

Phase

  • I

Study Id's

  • NCT01185964

  • NCT02451943

  • NCT02659020

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved